BLOG

THE AUSTRIAN CENTRE
OF INDUSTRIAL BIOTECHNOLOGY

acib is an international competence centre, developing new, environmentally friendly, economically and technically advanced processes for the biotechnological, pharmaceutical and chemical industry – all of them modelled on nature. acib is bridging the gap between academic research and producing industry. The big advantage for acib partner organisations is the possibility to translate scientific results into concrete processes and product by using scientific know-how, academic infrastructure or industrial networks. Our platform offers tailor-made solutions for our stakeholders from Academia, Industry and Investors.

 LATEST BLOG ARTICLES
  • Recycling of protective suits
  • The Lump Sum Pilot – virtue or curse?
  • When biotechnologists follow their noses
  • How microbiome studies can provide the basis to reduce food waste
  • The orchestra of yeast and its fragrance show
  • Carbon dioxide in a circular economy
  • Time for real-time monitoring of biopharma production
  • Open innovation – a case of “nothing ventured, nothing gained”
  • Gene switch in yeast discovered
  • Computer aided design of separation processes in pharmaceutical production

  • Recycling of protective suits

    We are living in a throwaway society; this is also true for clothes. When we think of the personal protective equipment for work safety such as mechanically robust and fire resistant clothes, it makes sense that they also have an expiration date. But that does not mean that also the ingredients have lost their functionality. Usually, these compounds have been produced with considerable energy effort, thus, it reasonable to find an efficient recycling method.

    Read more

  • The Lump Sum Pilot – virtue or curse?

    A new development in the European framework programs for research and innovation is catching attention: the lump sum pilot. First implementations are in progress already in Horizon 2020 and intensified for the next framework program Horizon Europe. What does it mean for the research community and which changes do we expect?

    Read more

  • When biotechnologists follow their noses

    It is grey, waxy, smelly and very expensive: Ambra, the worlds rarest organic substance, could only be found in the digestive tract of sperm whales. The compound is highly sought after by the perfume industry due to its fragrance fixative properties and distinctive aroma. Biotechnologists found a new biosynthetic pathway to produce the precursor of Ambra, names Ambrein, exactly as it occurs in nature. The findings could revolutionize the perfume industry by making different products eco-friendly.

    Read more

  • How microbiome studies can provide the basis to reduce food waste

    Plants, which are the primary source of food and animal feed, are not only affected by diseases during their growth but also following harvest and subsequent storage. Especially fungi that can efficiently degrade organic matter cause substantial losses of this valuable resource. Such losses can be prevented if adequate countermeasures are implemented. A recent study demonstrates how microbial markers can be used for the early detection of disease progression. Reliable biomarkers can be specifically targeted in the future to reduce food waste and to improve the storability of agricultural goods.

    Read more

  • The orchestra of yeast and its fragrance show

    Enzymes are playing the first violin, the cell is hosting a perfectly coordinated orchestra and reserachers are the composers? Instead of sounds they produce fragrances? Our musical thought experiment demonstrates the complex production processes of biotechnology with aromatics as an example.

    Read more

  • Carbon dioxide in a circular economy

    Carbon dioxide (CO2) emission is a massive problem for our climate; this is well-known. We urgently need measures to prevent earth from the big collapse. Where do we find them? Biotechnology offers some interesting solutions.

    Read more

  • Time for real-time monitoring of biopharma production

    While currently most production processes for biopharmaceuticals are assessed by laboriuos and time-consuming off-line analytics, a new process enables the monitoring of such processes in real-time. Sensors  combined with  mathematical models deliver information on the quality and quantity of the product, as well as on content and profile impurities. This allows an instant monitoring of processes, making processes safer, faster, cheaper and more efficient.

    Read more

  • Open innovation – a case of “nothing ventured, nothing gained”

    The modern business world is using a new buzzword: “Open innovation”. What does it mean? How “open” do we need to be? What could be the benefit? And what does it look like in reality?

    Read more

  • Gene switch in yeast discovered

    Scientists from the Department of Biotechnology at the University of Natural Resources and Life Sciences (BOKU) Vienna and the Austrian Centre of Industrial Biotechnology (acib) discovered a gene switch in yeast, that was able to change twelve genes – and thereby the metabolic process of yeast as a whole. This work explains evolutionary events that happened more than 120 million years ago. The results have recently been published in the scientific journal Nature Communications and have the potential to be used in the food and feed industry and for the production of bio fuels and new building blocks for bioplastics.

    Read more

  • Computer aided design of separation processes in pharmaceutical production

    Have you ever thought about how drugs are manufactured? They are often produced by microorganisms which secret them into their environment: a soup of media, the target drug and waste that must be eliminated. In the pharmaceutical industry, people use chromatography columns to purify the medication. This process is used for more than a century for the separation of compounds. One may think that everything should be already known for such a well-established process. Yet, acib researchers found out recently that already the connecting tubes and valves affect the quality of the separation process and – in the end – product quality.

    Read more

COMPANY PROFILE AND OWNERS

acib is an industrially oriented private limited company with a non-profit orientation. It is publicly owned by:

K2 RESEARCH CENTRE

acib is funded as a K2 research centre in the framework of FFG COMET funding (Competence Centres for Excellent Technologies) by BMVIT, BMWF, and the provinces of Styria, Vienna, Lower Austria and Tyrol. The COMET programme is processed via FFG. 18 scientific partners are involved in the implementation of the acib COMET programme, which is co-funded by 53 industrial partners.

More about COMET



Innovations from Nature 1
Innovations from Nature 4
Innovations from Nature 5
Innovations from Nature 2
Innovations from Nature 3
Innovations from Nature 6